GlassScriptPhysician profile
Nora Cantu
NPI 1275568065
$17,074.09
in general payments reported to CMS, 2019-2025
70 companies · $2,961 in 2025
The $2,961 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,164 · 2020: $1,849 · 2021: $2,467 · 2022: $2,444 · 2023: $2,355 · 2024: $2,834 · 2025: $2,961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,136 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,136.02 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,943.53 | 2021-2025 | Freestyle Libre 3, Cardiomems, Eterna |
| Novo Nordisk INC | $1,755.88 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,241.51 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $945.06 | 2019-2025 | Evenity, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $850.14 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $843.90 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $748.53 | 2019-2025 | Ubrelvy, Synthroid, Vraylar |
| Glaxosmithkline, LLC. | $713.03 | 2019-2025 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Bayer Healthcare Pharmaceuticals INC. | $601.89 | 2021-2025 | |
| Optinose US, INC. | $600.12 | 2019-2025 | |
| Pfizer INC. | $491.49 | 2019-2025 | |
| Amarin Pharma, INC. | $410.72 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $371.17 | 2019-2022 | |
| Astellas Pharma US INC | $369.06 | 2019-2025 | Veozah |
| Inspire Medical Systems, INC. | $356.67 | 2022-2025 | Inspire |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Cantu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.